BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Patel T. Cholangiocarcinoma--controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011;8:189-200. [PMID: 21460876 DOI: 10.1038/nrgastro.2011.20] [Cited by in Crossref: 204] [Cited by in F6Publishing: 242] [Article Influence: 20.4] [Reference Citation Analysis]
Number Citing Articles
1 Yamanaka T, Harimoto N, Yokobori T, Muranushi R, Hoshino K, Hagiwara K, Gantumur D, Handa T, Ishii N, Tsukagoshi M, Igarashi T, Tanaka H, Watanabe A, Kubo N, Araki K, Shirabe K. Nintedanib inhibits intrahepatic cholangiocarcinoma aggressiveness via suppression of cytokines extracted from activated cancer-associated fibroblasts. Br J Cancer. 2020;122:986-994. [PMID: 32015511 DOI: 10.1038/s41416-020-0744-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
2 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
3 Lee J, Yoon WS, Koom WS, Rim CH. Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review. Strahlenther Onkol 2019;195:93-102. [DOI: 10.1007/s00066-018-1367-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
4 Istanbouli A, Patel S, Almerey T, Li Z, Stauffer JA. Surgical Treatment for Intrahepatic, Peri-Hilar, and Distal Cholangiocarcinoma: 20-Single Institutional Year Experience. Am Surg 2021;:31348211034751. [PMID: 34314644 DOI: 10.1177/00031348211034751] [Reference Citation Analysis]
5 Haga H, Yan IK, Takahashi K, Wood J, Zubair A, Patel T. Tumour cell-derived extracellular vesicles interact with mesenchymal stem cells to modulate the microenvironment and enhance cholangiocarcinoma growth. J Extracell Vesicles. 2015;4:24900. [PMID: 25557794 DOI: 10.3402/jev.v4.24900] [Cited by in Crossref: 74] [Cited by in F6Publishing: 116] [Article Influence: 12.3] [Reference Citation Analysis]
6 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
7 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Cited by in Crossref: 473] [Cited by in F6Publishing: 451] [Article Influence: 94.6] [Reference Citation Analysis]
8 Taghizadeh H, Müllauer L, Mader R, Prager GW. Applied precision cancer medicine in metastatic biliary tract cancer. Hepatol Int 2020;14:288-95. [PMID: 32100259 DOI: 10.1007/s12072-020-10020-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
10 Zhou G, Boor PPC, Bruno MJ, Sprengers D, Kwekkeboom J. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers. Br J Cancer 2021. [PMID: 34400801 DOI: 10.1038/s41416-021-01453-3] [Reference Citation Analysis]
11 Acharya B, Chaijaroenkul W, Na-Bangchang K. Atractylodin inhibited the migration and induced autophagy in cholangiocarcinoma cells via PI3K/AKT/mTOR and p38MAPK signalling pathways. J Pharm Pharmacol 2021:rgab036. [PMID: 33885818 DOI: 10.1093/jpp/rgab036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
13 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
14 Kim JW, Jeong JB, Lee KL, Kim BG, Ahn DW, Lee JK, Kim SH. Comparison between uncovered and covered self-expandable metal stent placement in malignant duodenal obstruction. World J Gastroenterol 2015; 21(5): 1580-1587 [PMID: 25663777 DOI: 10.3748/wjg.v21.i5.1580] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
15 Lu L, Byrnes K, Han C, Wang Y, Wu T. miR-21 targets 15-PGDH and promotes cholangiocarcinoma growth. Mol Cancer Res 2014;12:890-900. [PMID: 24699315 DOI: 10.1158/1541-7786.MCR-13-0419] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 5.9] [Reference Citation Analysis]
16 Dutta S, Reamtong O, Panvongsa W, Kitdumrongthum S, Janpipatkul K, Sangvanich P, Piyachaturawat P, Chairoungdua A. Proteomics profiling of cholangiocarcinoma exosomes: A potential role of oncogenic protein transferring in cancer progression. Biochim Biophys Acta. 2015;1852:1989-1999. [PMID: 26148937 DOI: 10.1016/j.bbadis.2015.06.024] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
17 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
18 Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012;57:69-76. [PMID: 22420979 DOI: 10.1016/j.jhep.2012.02.022] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Kim YI, Park JW, Kim BH, Woo SM, Kim TH, Koh YH, Lee WJ, Kim CM. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma. Radiat Oncol. 2013;8:292. [PMID: 24359879 DOI: 10.1186/1748-717x-8-292] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
20 Navas MC, Glaser S, Dhruv H, Celinski S, Alpini G, Meng F. Hepatitis C Virus Infection and Cholangiocarcinoma: An Insight into Epidemiologic Evidences and Hypothetical Mechanisms of Oncogenesis. Am J Pathol 2019;189:1122-32. [PMID: 30953604 DOI: 10.1016/j.ajpath.2019.01.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
21 Zhang C, Wang H, Ning Z, Xu L, Zhuang L, Wang P, Meng Z. Serum liver enzymes serve as prognostic factors in patients with intrahepatic cholangiocarcinoma. Onco Targets Ther 2017;10:1441-9. [PMID: 28331337 DOI: 10.2147/OTT.S124161] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
22 Tusskorn O, Khunluck T, Prawan A, Senggunprai L, Kukongviriyapan V. Mitochondrial division inhibitor-1 potentiates cisplatin-induced apoptosis via the mitochondrial death pathway in cholangiocarcinoma cells. Biomed Pharmacother 2019;111:109-18. [PMID: 30579250 DOI: 10.1016/j.biopha.2018.12.051] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
23 Krawczyk M, Höblinger A, Mihalache F, Grünhage F, Acalovschi M, Lammert F, Zimmer V. Macrophage stimulating protein variation enhances the risk of sporadic extrahepatic cholangiocarcinoma. Dig Liver Dis 2013;45:612-5. [PMID: 23422030 DOI: 10.1016/j.dld.2012.12.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
24 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
25 Gong X, Zou L, Wang M, Zhang Y, Peng S, Zhong M, Zhou J, Li X, Ma X. Gramicidin inhibits cholangiocarcinoma cell growth by suppressing EGR4. Artif Cells Nanomed Biotechnol 2020;48:53-9. [PMID: 31852273 DOI: 10.1080/21691401.2019.1699808] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Joo I, Lee JM, Lee DH, Jeon JH, Han JK, Choi BI. Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout? Eur Radiol 2015;25:2859-68. [DOI: 10.1007/s00330-015-3686-3] [Cited by in Crossref: 89] [Cited by in F6Publishing: 79] [Article Influence: 14.8] [Reference Citation Analysis]
27 Berasain C, Avila MA. Platelet-derived growth factor D: a new player in the complex cross-talk between cholangiocarcinoma cells and cancer-associated fibroblasts. Hepatology 2013;58:853-5. [PMID: 23696149 DOI: 10.1002/hep.26476] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Mayr C, Beyreis M, Wagner A, Pichler M, Neureiter D, Kiesslich T. Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers. Biomed Res Int. 2016;2016:4805270. [PMID: 27957497 DOI: 10.1155/2016/4805270] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
29 Lee BS, Cha BH, Park EC, Roh J. Risk factors for perihilar cholangiocarcinoma: a hospital-based case-control study. Liver Int 2015;35:1048-53. [PMID: 24923595 DOI: 10.1111/liv.12618] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
30 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
31 You TM, Kim KD, Jeong HG, Park W. Mandibular metastasis of cholangiocarcinoma: A case report. Imaging Sci Dent 2015;45:247-51. [PMID: 26730373 DOI: 10.5624/isd.2015.45.4.247] [Reference Citation Analysis]
32 Massani M, Stecca T, Pauletti B, Marte G, Ruffolo C, Bonariol L, Bassi N. Intrahepatic Cholangiocarcinoma. In: Abdeldayem H, editor. Topics in the Surgery of the Biliary Tree. InTech; 2018. [DOI: 10.5772/intechopen.75516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Pangestu NS, Chueakwon P, Talabnin K, Khiaowichit J, Talabnin C. RNF43 overexpression attenuates the Wnt/β-catenin signalling pathway to suppress tumour progression in cholangiocarcinoma. Oncol Lett 2021;22:846. [PMID: 34733364 DOI: 10.3892/ol.2021.13107] [Reference Citation Analysis]
34 Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? J Hepatol. 2012;57:69-76. [PMID: 22420979 DOI: 10.1016/j.jhep.2012.02.022] [Cited by in Crossref: 276] [Cited by in F6Publishing: 302] [Article Influence: 30.7] [Reference Citation Analysis]
35 Lee DH, Kim B, Lee ES, Kim HJ, Min JH, Lee JM, Choi MH, Seo N, Choi SH, Kim SH, Lee SS, Park YS, Chung YE; Korean Society of Abdominal Radiology. Radiologic Evaluation and Structured Reporting Form for Extrahepatic Bile Duct Cancer: 2019 Consensus Recommendations from the Korean Society of Abdominal Radiology. Korean J Radiol 2021;22:41-62. [PMID: 32901457 DOI: 10.3348/kjr.2019.0803] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
36 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
37 Miyazaki M, Yoshitomi H, Miyakawa S, Uesaka K, Unno M, Endo I, Ota T, Ohtsuka M, Kinoshita H, Shimada K, Shimizu H, Tabata M, Chijiiwa K, Nagino M, Hirano S, Wakai T, Wada K, Isayama H, Okusaka T, Tsuyuguchi T, Fujita N, Furuse J, Yamao K, Murakami K, Yamazaki H, Kijima H, Nakanuma Y, Yoshida M, Takayashiki T, Takada T. Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition. J Hepatobiliary Pancreat Sci. 2015;22:249-273. [PMID: 25787274 DOI: 10.1002/jhbp.233] [Cited by in Crossref: 119] [Cited by in F6Publishing: 97] [Article Influence: 19.8] [Reference Citation Analysis]
38 Luo X, Yuan L, Wang Y, Ge R, Sun Y, Wei G. Survival outcomes and prognostic factors of surgical therapy for all potentially resectable intrahepatic cholangiocarcinoma: a large single-center cohort study. J Gastrointest Surg. 2014;18:562-572. [PMID: 24395070 DOI: 10.1007/s11605-013-2447-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 8.3] [Reference Citation Analysis]
39 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
40 Dee EC, Freret ME, Horick N, Raldow AC, Goyal L, Zhu AX, Parikh AR, Ryan DP, Clark JW, Allen JN, Ferrone CR, Fernandez-Del Castillo C, Tanabe KK, Drapek LC, Hong TS, Qadan M, Wo JY. Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. Ann Surg Oncol 2020;27:5161-72. [PMID: 32740733 DOI: 10.1245/s10434-020-08967-9] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
41 Serafini FM, Radvinsky D. The pathways of genetic transformation in cholangiocarcinogenesis. Cancer Genet 2016;209:554-8. [PMID: 27720541 DOI: 10.1016/j.cancergen.2016.07.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
42 Kim H, Hwang H, Lee H, Hong HJ. L1 Cell Adhesion Molecule Promotes Migration and Invasion via JNK Activation in Extrahepatic Cholangiocarcinoma Cells with Activating KRAS Mutation. Mol Cells 2017;40:363-70. [PMID: 28535665 DOI: 10.14348/molcells.2017.2282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
44 Arrington AK, Nelson RA, Falor A, Luu C, Wiatrek RL, Fakih M, Singh G, Kim J. Impact of medical and surgical intervention on survival in patients with cholangiocarcinoma. World J Gastrointest Surg 2013; 5(6): 178-186 [PMID: 23977420 DOI: 10.4240/wjgs.v5.i6.178] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
45 Goeppert B, Frauenschuh L, Zucknick M, Stenzinger A, Andrulis M, Klauschen F, Joehrens K, Warth A, Renner M, Mehrabi A. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br J Cancer. 2013;109:2665-2674. [PMID: 24136146 DOI: 10.1038/bjc.2013.610] [Cited by in Crossref: 105] [Cited by in F6Publishing: 104] [Article Influence: 13.1] [Reference Citation Analysis]
46 Agarwal R, Sendilnathan A, Siddiqi NI, Gulati S, Ghose A, Xie C, Olowokure OO. Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States. J Gastrointest Oncol 2016;7:996-1003. [PMID: 28078124 DOI: 10.21037/jgo.2016.09.10] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
47 Oliveira DV, Zhang S, Chen X, Calvisi DF, Andersen JB. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets. Expert Rev Gastroenterol Hepatol. 2017;11:349-356. [PMID: 28162004 DOI: 10.1080/17474124.2017.1292127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
48 Zhu YJ, Xu Q, Shao MY, Cao XY, Wu ZR, Chen YW, Bu H, Shi YJ. Decreased expression of HDAC8 indicates poor prognosis in patients with intrahepatic cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2019;18:464-70. [PMID: 31402267 DOI: 10.1016/j.hbpd.2019.07.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Onsurathum S, Haonon O, Pinlaor P, Pairojkul C, Khuntikeo N, Thanan R, Roytrakul S, Pinlaor S. Proteomics detection of S100A6 in tumor tissue interstitial fluid and evaluation of its potential as a biomarker of cholangiocarcinoma. Tumour Biol 2018;40:101042831876719. [DOI: 10.1177/1010428318767195] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
50 Kwon H, Song K, Han C, Zhang J, Lu L, Chen W, Wu T. Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway. Am J Pathol. 2017;187:2288-2299. [PMID: 28923203 DOI: 10.1016/j.ajpath.2017.06.014] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 9.5] [Reference Citation Analysis]
51 Hung SP, Huang BS, Hsieh CE, Lee CH, Tsang NM, Chang JT, Chen JS, Chou WC, Tseng JH, Hong JH. Clinical Outcomes of Patients With Unresectable Cholangiocarcinoma Treated With Proton Beam Therapy. Am J Clin Oncol 2020;43:180-6. [PMID: 31764017 DOI: 10.1097/COC.0000000000000646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
52 Mordvinov VA, Minkova GA, Kovner AV, Ponomarev DV, Lvova MN, Zaparina O, Romanenko SA, Shilov AG, Pakharukova MY. A tumorigenic cell line derived from a hamster cholangiocarcinoma associated with Opisthorchis felineus liver fluke infection. Life Sci 2021;277:119494. [PMID: 33862109 DOI: 10.1016/j.lfs.2021.119494] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
54 Howell JA, Khan SA. The role of miRNAs in cholangiocarcinoma. Hepat Oncol 2016;3:167-80. [PMID: 30191036 DOI: 10.2217/hep-2015-0003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
55 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
56 Huang B, Wu L, Lu XY, Xu F, Liu CF, Shen WF, Jia NY, Cheng HY, Yang YF, Shen F. Small Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in Cirrhotic Livers May Share Similar Enhancement Patterns at Multiphase Dynamic MR Imaging. Radiology. 2016;281:150-157. [PMID: 27077381 DOI: 10.1148/radiol.2016151205] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 9.4] [Reference Citation Analysis]
57 Bragazzi MC, Ridola L, Safarikia S, Matteo SD, Costantini D, Nevi L, Cardinale V. New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin. Ann Gastroenterol. 2018;31:42-55. [PMID: 29333066 DOI: 10.20524/aog.2017.0209] [Cited by in Crossref: 13] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
58 Kongpetch S, Kukongviriyapan V, Prawan A, Senggunprai L, Kukongviriyapan U, Buranrat B. Crucial role of heme oxygenase-1 on the sensitivity of cholangiocarcinoma cells to chemotherapeutic agents. PLoS One 2012;7:e34994. [PMID: 22514698 DOI: 10.1371/journal.pone.0034994] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 5.7] [Reference Citation Analysis]
59 Nagino M. Perihilar cholangiocarcinoma: a surgeon’s viewpoint on current topics. J Gastroenterol. 2012;47:1165-1176. [PMID: 22847554 DOI: 10.1007/s00535-012-0628-6] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
60 Xia Y, Gao Y, Wang B, Zhang H, Zhang Q. Optimizing the Method of Cell Separation from Bile of Patients with Cholangiocarcinoma for Flow Cytometry. Gastroenterol Res Pract 2019;2019:5436961. [PMID: 31191647 DOI: 10.1155/2019/5436961] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Taghizadeh H, Unseld M, Schmiderer A, Djanani A, Wilthoner K, Buchinger D, Prager GW. First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer. Cancer Chemother Pharmacol 2020;86:109-15. [PMID: 32556829 DOI: 10.1007/s00280-020-04094-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
62 Maroni L, Pierantonelli I, Banales JM, Benedetti A, Marzioni M. The significance of genetics for cholangiocarcinoma development. Ann Transl Med 2013;1:28. [PMID: 25332972 DOI: 10.3978/j.issn.2305-5839.2012.10.04] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
63 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
64 Li M, Li J, Li P, Li H, Su T, Zhu R, Gong J. Hepatitis B virus infection increases the risk of cholangiocarcinoma: a meta-analysis and systematic review. J Gastroenterol Hepatol. 2012;27:1561-1568. [PMID: 22694354 DOI: 10.1111/j.1440-1746.2012.07207.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 7.1] [Reference Citation Analysis]
65 An F, Olaru AV, Mezey E, Xie Q, Li L, Piontek KB, Selaru FM. MicroRNA-224 Induces G1/S Checkpoint Release in Liver Cancer. J Clin Med 2015;4:1713-28. [PMID: 26343737 DOI: 10.3390/jcm4091713] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
66 Farioli A, Straif K, Brandi G, Curti S, Kjaerheim K, Martinsen JI, Sparen P, Tryggvadottir L, Weiderpass E, Biasco G, Violante FS, Mattioli S, Pukkala E. Occupational exposure to asbestos and risk of cholangiocarcinoma: a population-based case-control study in four Nordic countries. Occup Environ Med 2018;75:191-8. [PMID: 29133597 DOI: 10.1136/oemed-2017-104603] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
67 Martin SP, Ruff S, Diggs LP, Drake J, Ayabe RI, Brown ZJ, Wach MM, Steinberg SM, Davis JL, Hernandez JM. Tumor grade and sex should influence the utilization of portal lymphadenectomy for early stage intrahepatic cholangiocarcinoma. HPB (Oxford) 2019;21:419-24. [PMID: 30139566 DOI: 10.1016/j.hpb.2018.07.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
68 Patel T. Clinical diagnosis and management of intrahepatic cholangiocarcinoma. Clin Liver Dis (Hoboken) 2014;3:56-9. [PMID: 30992886 DOI: 10.1002/cld.324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
69 Woo SM, Kim DH, Lee WJ, Park KW, Park SJ, Han SS, Kim TH, Koh YH, Kim HB, Hong EK. Comparison of uncovered and covered stents for the treatment of malignant duodenal obstruction caused by pancreaticobiliary cancer. Surg Endosc. 2013;27:2031-2039. [PMID: 23288317 DOI: 10.1007/s00464-012-2705-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
70 Martin SP, Drake J, Wach MM, Ruff S, Diggs LP, Wan JY, Brown ZJ, Ayabe RI, Glazer ES, Dickson PV, Davis JL, Deneve JL, Hernandez JM. Laparoscopic Approach to Intrahepatic Cholangiocarcinoma is Associated with an Exacerbation of Inadequate Nodal Staging. Ann Surg Oncol 2019;26:1851-7. [PMID: 30895496 DOI: 10.1245/s10434-019-07303-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
71 Yue XJ, Xu LB, Zhu MS, Zhang R, Liu C. Over-expression of nerve growth factor-β in human cholangiocarcinoma QBC939 cells promote tumor progression. PLoS One. 2013;8:e62024. [PMID: 23637956 DOI: 10.1371/journal.pone.0062024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
72 Sritana N, Suriyo T, Kanitwithayanun J, Songvasin BH, Thiantanawat A, Satayavivad J. Glyphosate induces growth of estrogen receptor alpha positive cholangiocarcinoma cells via non-genomic estrogen receptor/ERK1/2 signaling pathway. Food and Chemical Toxicology 2018;118:595-607. [DOI: 10.1016/j.fct.2018.06.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
73 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
74 Yamaoka R, Ishii T, Kawai T, Yasuchika K, Miyauchi Y, Kojima H, Katayama H, Ogiso S, Fukumitsu K, Uemoto S. CD90 expression in human intrahepatic cholangiocarcinoma is associated with lymph node metastasis and poor prognosis: YAMAOKA et al.. J Surg Oncol 2018;118:664-74. [DOI: 10.1002/jso.25192] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
75 Konstantinidis IT, Do RK, Gultekin DH, Gönen M, Schwartz LH, Fong Y, Allen PJ, D’Angelica MI, DeMatteo RP, Klimstra DS. Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. Ann Surg Oncol. 2014;21:2675-2683. [PMID: 24664624 DOI: 10.1245/s10434-014-3649-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
76 Yu TH, Chen X, Zhang XH, Zhang EC, Sun CX. Clinicopathological characteristics and prognostic factors for intrahepatic cholangiocarcinoma: a population-based study. Sci Rep 2021;11:3990. [PMID: 33597569 DOI: 10.1038/s41598-021-83149-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Khoontawad J, Hongsrichan N, Chamgramol Y, Pinlaor P, Wongkham C, Yongvanit P, Pairojkul C, Khuntikeo N, Roytrakul S, Boonmars T, Pinlaor S. Increase of exostosin 1 in plasma as a potential biomarker for opisthorchiasis-associated cholangiocarcinoma. Tumour Biol 2014;35:1029-39. [PMID: 24018821 DOI: 10.1007/s13277-013-1137-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
78 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
79 Bergeat D, Fautrel A, Turlin B, Merdrignac A, Rayar M, Boudjema K, Coulouarn C, Sulpice L. Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma. Journal of Surgical Research 2016;203:441-50. [DOI: 10.1016/j.jss.2016.03.044] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
80 Lamarca A, Ross P, Wasan HS, Hubner RA, McNamara MG, Lopes A, Manoharan P, Palmer D, Bridgewater J, Valle JW. Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials. J Natl Cancer Inst. 2020;112:200-210. [PMID: 31077311 DOI: 10.1093/jnci/djz071] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 24.0] [Reference Citation Analysis]
81 Rose JB, Correa-Gallego C, Li Y, Nelson J, Alseidi A, Helton WS, Allen PJ, D'Angelica MI, DeMatteo RP, Fong Y, Kingham TP, Kowdley KV, Jarnagin WR, Rocha FG. The Role of Biliary Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 6 (CEACAM6) as a Biomarker in Cholangiocarcinoma. PLoS One 2016;11:e0150195. [PMID: 26974538 DOI: 10.1371/journal.pone.0150195] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
82 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
83 Hoyos S, Navas MC, Restrepo JC, Botero RC. Current controversies in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1461-1467. [PMID: 28756216 DOI: 10.1016/j.bbadis.2017.07.027] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
84 Sun C, Zhu J, Wu B, Chen J, Zhu Z, Cai P, Guo W, Gu Z, Wang J, Huang S. Diagnostic and prognostic value of microRNAs in cholangiocarcinoma: a systematic review and meta-analysis. Cancer Manag Res 2018;10:2125-39. [PMID: 30050323 DOI: 10.2147/CMAR.S158155] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
85 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
86 Bartolini I, Risaliti M, Fortuna L, Agostini C, Ringressi MN, Taddei A, Muiesan P. Current management of intrahepatic cholangiocarcinoma: from resection to palliative treatments. Radiol Oncol 2020;54:263-71. [PMID: 32726292 DOI: 10.2478/raon-2020-0045] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
87 Guan L, Zhang L, Gong Z, Hou X, Xu Y, Feng X, Wang H, You H. FoxO3 inactivation promotes human cholangiocarcinoma tumorigenesis and chemoresistance through Keap1-Nrf2 signaling. Hepatology 2016;63:1914-27. [PMID: 26857210 DOI: 10.1002/hep.28496] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 9.0] [Reference Citation Analysis]
88 Boilève A, Verlingue L, Hollebecque A, Boige V, Ducreux M, Malka D. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers. Expert Opin Investig Drugs 2021;30:401-9. [PMID: 33641556 DOI: 10.1080/13543784.2021.1896703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Zhang C, Wang H, Ning Z, Xu L, Zhuang L, Wang P, Meng Z. Prognostic nutritional index serves as a predictive marker of survival and associates with systemic inflammatory response in metastatic intrahepatic cholangiocarcinoma. Onco Targets Ther. 2016;9:6417-6423. [PMID: 27799789 DOI: 10.2147/ott.s112501] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 4.4] [Reference Citation Analysis]
90 Mamone G, Marrone G, Caruso S, Carollo V, Gentile G, Crino' F, Milazzo M, Luca A. Intrahepatic mass-forming cholangiocarcinoma: enhancement pattern on Gd-BOPTA-MRI with emphasis of hepatobiliary phase. Abdom Imaging 2015;40:2313-22. [PMID: 25962708 DOI: 10.1007/s00261-015-0445-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
91 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
92 Kiesslich T, Mayr C, Wachter J, Bach D, Fuereder J, Wagner A, Alinger B, Pichler M, Di Fazio P, Ocker M. Activated hedgehog pathway is a potential target for pharmacological intervention in biliary tract cancer. Mol Cell Biochem. 2014;396:257-268. [PMID: 25064451 DOI: 10.1007/s11010-014-2161-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
93 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
94 Toyoda Y, Takada T, Suzuki H. Halogenated hydrocarbon solvent-related cholangiocarcinoma risk: biliary excretion of glutathione conjugates of 1,2-dichloropropane evidenced by untargeted metabolomics analysis. Sci Rep 2016;6:24586. [PMID: 27087417 DOI: 10.1038/srep24586] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
95 Ikeda C, Haga H, Makino N, Inuzuka T, Kurimoto A, Ueda T, Matsuda A, Kakizaki Y, Ishizawa T, Kobayashi T, Sugahara S, Tsunoda M, Suda K, Ueno Y. Utility of Claudin-3 in extracellular vesicles from human bile as biomarkers of cholangiocarcinoma. Sci Rep 2021;11:1195. [PMID: 33441949 DOI: 10.1038/s41598-021-81023-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Deng M, Li SH, Fu X, Yan XP, Chen J, Qiu YD, Guo RP. Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients. Cancer Cell Int 2021;21:371. [PMID: 34253205 DOI: 10.1186/s12935-021-02081-w] [Reference Citation Analysis]
97 Balasubramanian B, Venkatraman S, Myint KZ, Janvilisri T, Wongprasert K, Kumkate S, Bates DO, Tohtong R. Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma. Pharmaceuticals (Basel) 2021;14:51. [PMID: 33440754 DOI: 10.3390/ph14010051] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
99 Mayr C, Ocker M, Ritter M, Pichler M, Neureiter D, Kiesslich T. Biliary tract cancer stem cells - translational options and challenges. World J Gastroenterol 2017; 23(14): 2470-2482 [PMID: 28465631 DOI: 10.3748/wjg.v23.i14.2470] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
100 Li L, Masica D, Ishida M, Tomuleasa C, Umegaki S, Kalloo AN, Georgiades C, Singh VK, Khashab M, Amateau S, Li Z, Okolo P, Lennon AM, Saxena P, Geschwind JF, Schlachter T, Hong K, Pawlik TM, Canto M, Law J, Sharaiha R, Weiss CR, Thuluvath P, Goggins M, Shin EJ, Peng H, Kumbhari V, Hutfless S, Zhou L, Mezey E, Meltzer SJ, Karchin R, Selaru FM. Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology 2014;60:896-907. [PMID: 24497320 DOI: 10.1002/hep.27050] [Cited by in Crossref: 121] [Cited by in F6Publishing: 173] [Article Influence: 17.3] [Reference Citation Analysis]
101 Xie W, Wei L, Guo J, Guo H, Song X, Sheng X. Physiological functions of Wilms’ tumor 1‐associating protein and its role in tumourigenesis. J Cell Biochem 2019;120:10884-92. [DOI: 10.1002/jcb.28402] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
102 Mayr C, Neureiter D, Wagner A, Pichler M, Kiesslich T. The role of polycomb repressive complexes in biliary tract cancer. Expert Opin Ther Targets 2015;19:363-75. [PMID: 25424424 DOI: 10.1517/14728222.2014.986460] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
103 Simile MM, Bagella P, Vidili G, Spanu A, Manetti R, Seddaiu MA, Babudieri S, Madeddu G, Serra PA, Altana M, Paliogiannis P. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials. Medicina (Kaunas) 2019;55:E42. [PMID: 30743998 DOI: 10.3390/medicina55020042] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
104 Navaneethan U, Njei B, Lourdusamy V, Konjeti R, Vargo JJ, Parsi MA. Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc. 2015;81:168-176. [PMID: 25440678 DOI: 10.1016/j.gie.2014.09.017] [Cited by in Crossref: 177] [Cited by in F6Publishing: 188] [Article Influence: 25.3] [Reference Citation Analysis]
105 Giordano S, Takeda S, Donadon M, Saiki H, Brunelli L, Pastorelli R, Cimino M, Soldani C, Franceschini B, Di Tommaso L, Lleo A, Yoshimura K, Nakajima H, Torzilli G, Davoli E. Rapid automated diagnosis of primary hepatic tumour by mass spectrometry and artificial intelligence. Liver Int 2020;40:3117-24. [PMID: 32662575 DOI: 10.1111/liv.14604] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
106 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
107 Bergeat D, Turrini O, Courtin-tanguy L, Truant S, Darnis B, Delpero JR, Mabrut J, Regenet N, Sulpice L. Impact of adjuvant chemotherapy after pancreaticoduodenectomy for distal cholangiocarcinoma: a propensity score analysis from a French multicentric cohort. Langenbecks Arch Surg 2018;403:701-9. [DOI: 10.1007/s00423-018-1702-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
108 Zhang J, Han C, Zhu H, Song K, Wu T. miR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF). Am J Pathol 2013;182:1629-39. [PMID: 23608225 DOI: 10.1016/j.ajpath.2013.01.045] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
109 Permpoon U, Khan F, Vadevoo SMP, Gurung S, Gunassekaran GR, Kim MJ, Kim SH, Thuwajit P, Lee B. Inhibition of Tumor Growth against Chemoresistant Cholangiocarcinoma by a Proapoptotic Peptide Targeting Interleukin-4 Receptor. Mol Pharm 2020;17:4077-88. [PMID: 32881535 DOI: 10.1021/acs.molpharmaceut.0c00529] [Reference Citation Analysis]
110 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
111 Kang MJ, Lim J, Han SS, Park HM, Kim SW, Won YJ, Park SJ. Impact of changes in the topographic classification of Klatskin tumor on incidence of intra- and extrahepatic bile duct cancer: A population-based national cancer registry study. J Hepatobiliary Pancreat Sci 2021. [PMID: 33615747 DOI: 10.1002/jhbp.916] [Reference Citation Analysis]
112 Tusskorn O, Khunluck T, Prawan A, Senggunprai L, Kukongviriyapan U, Kukongviriyapan V. Suppression of glutathione S-transferases potentiates the cytotoxic effect of phenethyl isothiocyanate in cholangiocarcinoma cells. Naunyn Schmiedebergs Arch Pharmacol 2018;391:657-67. [PMID: 29666895 DOI: 10.1007/s00210-018-1492-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
113 Song W, Miao DL, Chen L. Survival rates are higher in married patients with biliary tract cancer: a population-based study. Oncotarget 2018;9:9531-9. [PMID: 29507708 DOI: 10.18632/oncotarget.24170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
114 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
115 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
116 Yao L, Han C, Song K, Zhang J, Lim K, Wu T. Omega-3 Polyunsaturated Fatty Acids Upregulate 15-PGDH Expression in Cholangiocarcinoma Cells by Inhibiting miR-26a/b Expression. Cancer Res 2015;75:1388-98. [PMID: 25691459 DOI: 10.1158/0008-5472.CAN-14-2561] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
117 Heo JY, Lee HS, Son JH, Lee SH, Bang S. Clinical Outcomes of Bilateral Stent-in-Stent Placement Using Self-Expandable Metallic Stent for High-Grade Malignant Hilar Biliary Obstruction. Yonsei Med J. 2018;59:827-833. [PMID: 30091315 DOI: 10.3349/ymj.2018.59.7.827] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
118 Park HS, Park JS, Chun YJ, Roh YH, Moon J, Chon HJ, Choi HJ, Park JS, Lee DK, Lee SJ, Yoon DS, Jeung HC. Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer. Cancer Res Treat 2017;49:1127-39. [PMID: 28161931 DOI: 10.4143/crt.2016.538] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
119 Conci S, Ruzzenente A, Simbolo M, Bagante F, Rusev B, Isa G, Lawlor RT, Pedrazzani C, Iacono C, Guglielmi A, Scarpa A. Multigene mutational profiling of biliary tract cancer is related to the pattern of recurrence in surgically resected patients. Updates Surg 2020;72:119-28. [PMID: 32020551 DOI: 10.1007/s13304-020-00718-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
120 Tusskorn O, Prawan A, Senggunprai L, Kukongviriyapan U, Kukongviriyapan V. Phenethyl isothiocyanate induces apoptosis of cholangiocarcinoma cells through interruption of glutathione and mitochondrial pathway. Naunyn Schmiedebergs Arch Pharmacol 2013;386:1009-16. [PMID: 23949086 DOI: 10.1007/s00210-013-0906-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
121 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
122 Forner A, Vilana R, Bianchi L, Rodríguez-lope C, Reig M, García-criado MÁ, Rimola J, Solé M, Ayuso C, Bru C, Bruix J. Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2cm. Journal of Hepatology 2015;62:150-5. [DOI: 10.1016/j.jhep.2014.08.028] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
123 Yin X, Chai Z, Sun X, Chen J, Wu X, Yang L, Zhou X, Liu F. Overexpression of microRNA-96 is associated with poor prognosis and promotes proliferation, migration and invasion in cholangiocarcinoma cells via MTSS1. Exp Ther Med 2020;19:2757-65. [PMID: 32256758 DOI: 10.3892/etm.2020.8502] [Reference Citation Analysis]
124 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
125 Jung P, Cho EH, Kim SB, Kim RG. Comparison of the clinical results of surgical resection for extrahepatic cholangiocarcinomas: Hilar cholangiocarcinoma and mid-to-distal cholangiocarcinoma. Ann Hepatobiliary Pancreat Surg 2019;23:319-26. [PMID: 31824996 DOI: 10.14701/ahbps.2019.23.4.319] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
126 Yu WL, Yu G, Dong H, Chen K, Xie J, Yu H, Ji Y, Yang GS, Li AJ, Cong WM, Jin GZ. Proteomics analysis identified TPI1 as a novel biomarker for predicting recurrence of intrahepatic cholangiocarcinoma. J Gastroenterol 2020;55:1171-82. [PMID: 33089343 DOI: 10.1007/s00535-020-01729-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
127 Kariya CM, Wach MM, Ruff SM, Ayabe RI, Lo WM, Torres MB, Petrick JL, McNeel TS, Davis JL, McGlynn KA, Hernandez JM. Postbiliary drainage rates of cholangitis are impacted by procedural technique for patients with supra-ampullary cholangiocarcinoma: A SEER-Medicare analysis. J Surg Oncol 2019;120:249-55. [PMID: 31044430 DOI: 10.1002/jso.25485] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 Massalha H, Bahar Halpern K, Abu-Gazala S, Jana T, Massasa EE, Moor AE, Buchauer L, Rozenberg M, Pikarsky E, Amit I, Zamir G, Itzkovitz S. A single cell atlas of the human liver tumor microenvironment. Mol Syst Biol 2020;16:e9682. [PMID: 33332768 DOI: 10.15252/msb.20209682] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
129 Chen BD, Zhao WC, Dong JD, Sima H. Expression of GLP-1R protein and its clinical role in intrahepatic cholangiocarcinoma tissues. Mol Biol Rep 2014;41:4313-20. [PMID: 24577752 DOI: 10.1007/s11033-014-3302-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
130 Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-wahab R, Gupta N, Mobley CM, Saharia A, Victor DW, Nguyen DT, Graviss EA, Kaseb AO, Mcfadden RS, Aloia TA, Conrad C, Li XC, Monsour HP, Gaber AO, Vauthey J, Ghobrial RM. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. The Lancet Gastroenterology & Hepatology 2018;3:337-48. [DOI: 10.1016/s2468-1253(18)30045-1] [Cited by in Crossref: 74] [Cited by in F6Publishing: 33] [Article Influence: 24.7] [Reference Citation Analysis]
131 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
132 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
133 Chen X, Calvisi DF. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol. 2014;184:912-923. [PMID: 24480331 DOI: 10.1016/j.ajpath.2013.12.002] [Cited by in Crossref: 166] [Cited by in F6Publishing: 165] [Article Influence: 23.7] [Reference Citation Analysis]
134 Ariizumi S, Yamamoto M. Intrahepatic cholangiocarcinoma and cholangiolocellular carcinoma in cirrhosis and chronic viral hepatitis. Surg Today 2015;45:682-7. [PMID: 25253466 DOI: 10.1007/s00595-014-1031-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
135 Marti P, Stein C, Blumer T, Abraham Y, Dill MT, Pikiolek M, Orsini V, Jurisic G, Megel P, Makowska Z, Agarinis C, Tornillo L, Bouwmeester T, Ruffner H, Bauer A, Parker CN, Schmelzle T, Terracciano LM, Heim MH, Tchorz JS. YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors. Hepatology 2015;62:1497-510. [PMID: 26173433 DOI: 10.1002/hep.27992] [Cited by in Crossref: 109] [Cited by in F6Publishing: 116] [Article Influence: 18.2] [Reference Citation Analysis]
136 Buckholz AP, Brown RS Jr. Cholangiocarcinoma: Diagnosis and Management. Clin Liver Dis 2020;24:421-36. [PMID: 32620281 DOI: 10.1016/j.cld.2020.04.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
137 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
138 Rucksaken R, Charoensuk L, Pinlaor P, Pairojkul C, Khuntikeo N, Pinlaor S. Plasma orosomucoid 2 as a potential risk marker of cholangiocarcinoma. Cancer Biomark 2017;18:27-34. [PMID: 27814272 DOI: 10.3233/CBM-160670] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
139 Vaeteewoottacharn K, Kariya R, Matsuda K, Taura M, Wongkham C, Wongkham S, Okada S. Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma. J Cancer Res Clin Oncol. 2013;139:1551-1562. [PMID: 23877657 DOI: 10.1007/s00432-013-1473-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
140 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
141 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
142 Bae BC, Yang SG, Jeong S, Lee DH, Na K, Kim JM, Costamagna G, Kozarek RA, Isayama H, Deviere J, Seo DW, Nageshwar Reddy D. Polymeric photosensitizer-embedded self-expanding metal stent for repeatable endoscopic photodynamic therapy of cholangiocarcinoma. Biomaterials. 2014;35:8487-8495. [PMID: 25043500 DOI: 10.1016/j.biomaterials.2014.07.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
143 Lee HM, Jeong YI, Kim DH, Kwak TW, Chung CW, Kim CH, Kang DH. Ursodeoxycholic acid-conjugated chitosan for photodynamic treatment of HuCC-T1 human cholangiocarcinoma cells. Int J Pharm 2013;454:74-81. [PMID: 23834828 DOI: 10.1016/j.ijpharm.2013.06.035] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
144 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
145 Butsri S, Kukongviriyapan V, Senggunprai L, Kongpetch S, Zeekpudsa P, Prawan A. Downregulation of NAD(P)H:quinone oxidoreductase 1 inhibits proliferation, cell cycle and migration of cholangiocarcinoma cells. Oncol Lett 2017;13:4540-8. [PMID: 28599455 DOI: 10.3892/ol.2017.5951] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
146 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
147 Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2012;9:44-54. [DOI: 10.1038/nrgastro.2011.222] [Cited by in Crossref: 95] [Cited by in F6Publishing: 134] [Article Influence: 9.5] [Reference Citation Analysis]
148 Lee BS, Hwang JH, Lee SH, Jang SE, Ahn DW, Hwang DW, Cho JY, Yoon YS, Han HS, Ahn S. Older adults with biliary tract cancer: treatment and prognosis. J Am Geriatr Soc 2012;60:1862-71. [PMID: 23035728 DOI: 10.1111/j.1532-5415.2012.04163.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
149 Patel T. New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma. J Gastroenterol 2014;49:165-72. [PMID: 24145988 DOI: 10.1007/s00535-013-0894-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
150 Amonyingcharoen S, Suriyo T, Thiantanawat A, Watcharasit P, Satayavivad J. Taurolithocholic acid promotes intrahepatic cholangiocarcinoma cell growth via muscarinic acetylcholine receptor and EGFR/ERK1/2 signaling pathway. Int J Oncol 2015;46:2317-26. [PMID: 25815516 DOI: 10.3892/ijo.2015.2939] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
151 Ierardi AM, Angileri SA, Patella F, Panella S, Lucchina N, Petre EN, Pinto A, Franceschelli G, Carrafiello G, Cornalba G, Sofocleous CT. The role of interventional radiology in the treatment of intrahepatic cholangiocarcinoma. Med Oncol 2017;34:11. [PMID: 28008570 DOI: 10.1007/s12032-016-0866-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
152 Wiggans MG, Jackson SA, Fox BM, Mitchell JD, Aroori S, Bowles MJ, Armstrong EM, Shirley JF, Stell DA. The Preoperative Assessment of Hepatic Tumours: Evaluation of UK Regional Multidisciplinary Team Performance. HPB Surg 2013;2013:861681. [PMID: 24062601 DOI: 10.1155/2013/861681] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
153 Fischer SE. Recurrent and de novo malignancies following liver transplantation. Diagnostic Histopathology 2012;18:290-6. [DOI: 10.1016/j.mpdhp.2012.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
154 Utuama O, Permuth JB, Dagne G, Sanchez-Anguiano A, Alman A, Kumar A, Denbo J, Kim R, Fleming JB, Anaya DA. Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Propensity Score Survival Analysis Supporting Use in Patients with High-Risk Disease. Ann Surg Oncol 2021;28:1939-49. [PMID: 33415559 DOI: 10.1245/s10434-020-09478-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
155 Guo S, Liu H, Liu Y, Liu L, Sun Q, Cui X. Hepatoma-derived growth factor: a novel prognostic biomarker in intrahepatic cholangiocarcinoma. Tumor Biol 2015;36:353-64. [DOI: 10.1007/s13277-014-2651-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
156 Ota Y, Takahashi K, Otake S, Tamaki Y, Okada M, Aso K, Makino Y, Fujii S, Ota T, Haneda M. Extracellular vesicle-encapsulated miR-30e suppresses cholangiocarcinoma cell invasion and migration via inhibiting epithelial-mesenchymal transition. Oncotarget. 2018;9:16400-16417. [PMID: 29662654 DOI: 10.18632/oncotarget.24711] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
157 Doherty B, Nambudiri VE, Palmer WC. Update on the Diagnosis and Treatment of Cholangiocarcinoma. Curr Gastroenterol Rep. 2017;19:2. [PMID: 28110453 DOI: 10.1007/s11894-017-0542-4] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 17.5] [Reference Citation Analysis]
158 Li S, Mao M. Next generation sequencing reveals genetic landscape of hepatocellular carcinomas. Cancer Lett. 2013;340:247-253. [PMID: 23063663 DOI: 10.1016/j.canlet.2012.09.027] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
159 Labib PL, Davidson BR, Sharma RA, Pereira SP. Locoregional therapies in cholangiocarcinoma. Hepat Oncol 2017;4:99-109. [PMID: 29367874 DOI: 10.2217/hep-2017-0014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
160 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
161 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
162 Cheng R, Du Q, Ye J, Wang B, Chen Y. Prognostic value of site-specific metastases for patients with advanced intrahepatic cholangiocarcinoma: A SEER database analysis. Medicine (Baltimore) 2019;98:e18191. [PMID: 31804337 DOI: 10.1097/MD.0000000000018191] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
163 Jeong HT, Kim MJ, Chung YE, Choi JY, Park YN, Kim KW. Gadoxetate disodium-enhanced MRI of mass-forming intrahepatic cholangiocarcinomas: imaging-histologic correlation. AJR Am J Roentgenol. 2013;201:W603-W611. [PMID: 24059399 DOI: 10.2214/ajr.12.10262] [Cited by in Crossref: 49] [Cited by in F6Publishing: 20] [Article Influence: 6.1] [Reference Citation Analysis]
164 Haga H, Patel T. Molecular diagnosis of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2015;22:114-23. [PMID: 25267595 DOI: 10.1002/jhbp.156] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
165 Na-Bangchang K, Plengsuriyakarn T, Karbwang J. Research and Development of Atractylodes lancea (Thunb) DC. as a Promising Candidate for Cholangiocarcinoma Chemotherapeutics. Evid Based Complement Alternat Med 2017;2017:5929234. [PMID: 29348769 DOI: 10.1155/2017/5929234] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
166 Xie Y, Wehrkamp CJ, Li J, Wang Y, Wang Y, Mott JL, Oupický D. Delivery of miR-200c Mimic with Poly(amido amine) CXCR4 Antagonists for Combined Inhibition of Cholangiocarcinoma Cell Invasiveness. Mol Pharm 2016;13:1073-80. [PMID: 26855082 DOI: 10.1021/acs.molpharmaceut.5b00894] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
167 Du N, Song LP, Li XS, Wang L, Wan L, Ma HY, Zhao H. Novel pH-sensitive nanoformulated docetaxel as a potential therapeutic strategy for the treatment of cholangiocarcinoma. J Nanobiotechnology 2015;13:17. [PMID: 25889600 DOI: 10.1186/s12951-015-0066-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
168 Heuer M, Dreger NM, Cicinnati VR, Fingas C, Juntermanns B, Paul A, Kaiser GM. Tumor growth effects of rapamycin on human biliary tract cancer cells. Eur J Med Res 2012;17:20. [PMID: 22721369 DOI: 10.1186/2047-783X-17-20] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
169 Lee CU, Glockner JF. MRI of common and uncommon pathologies involving the periportal space: a pictorial essay. Abdom Radiol (NY) 2016;41:149-61. [PMID: 26830621 DOI: 10.1007/s00261-015-0598-2] [Reference Citation Analysis]
170 Ou Yang Q, Zhang S, Cheng QB, Li B, Feng FL, Yu Y, Luo XJ, Lin ZF, Jiang XQ. Dynamic Change of Total Bilirubin after Portal Vein Embolization is Predictive of Major Complications and Posthepatectomy Mortality in Patients with Hilar Cholangiocarcinoma. J Gastrointest Surg 2016;20:960-9. [PMID: 26831059 DOI: 10.1007/s11605-016-3086-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
171 Li L, Piontek K, Ishida M, Fausther M, Dranoff JA, Fu R, Mezey E, Gould SJ, Fordjour FK, Meltzer SJ, Sirica AE, Selaru FM. Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model. Hepatology. 2017;65:501-514. [PMID: 27474881 DOI: 10.1002/hep.28735] [Cited by in Crossref: 61] [Cited by in F6Publishing: 71] [Article Influence: 12.2] [Reference Citation Analysis]
172 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
173 Li Y, Ke Y, Zou H, Wang K, Huang S, Rengarajan T, Wang L. Gold nano particles synthesized from Strychni semen and its anticancer activity in cholangiocarcinoma cell (KMCH-1). Artif Cells Nanomed Biotechnol 2019;47:1610-6. [PMID: 31072209 DOI: 10.1080/21691401.2019.1594860] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
174 Tasch JJ, Dube N. An Unusual Presentation of Advanced Intrahepatic Cholangiocarcinoma: When Biopsy Results Fail. Am J Case Rep 2018;19:35-40. [PMID: 29317591 DOI: 10.12659/ajcr.906165] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
175 Wan J, Ye L, Yang X, Guo Q, Wang K, Huang Z, Tan Y, Yuan B, Xie Q. Cell-SELEX based selection and optimization of DNA aptamers for specific recognition of human cholangiocarcinoma QBC-939 cells. Analyst 2015;140:5992-7. [PMID: 26181902 DOI: 10.1039/c5an01055a] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
176 van Keulen AM, Buettner S, Besselink MG, Busch OR, van Gulik TM, Ijzermans JNM, de Jonge J, Polak WG, Swijnenburg RJ, Groot Koerkamp B, Erdmann JI, Olthof PB. Surgical morbidity in the first year after resection for perihilar cholangiocarcinoma. HPB (Oxford) 2021:S1365-182X(21)00098-8. [PMID: 33947606 DOI: 10.1016/j.hpb.2021.03.016] [Reference Citation Analysis]
177 Tusskorn O, Senggunprai L, Prawan A, Kukongviriyapan U, Kukongviriyapan V. Phenethyl isothiocyanate induces calcium mobilization and mitochondrial cell death pathway in cholangiocarcinoma KKU-M214 cells. BMC Cancer 2013;13:571. [PMID: 24304591 DOI: 10.1186/1471-2407-13-571] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
178 Kongpetch S, Puapairoj A, Ong CK, Senggunprai L, Prawan A, Kukongviriyapan U, Chan-On W, Siew EY, Khuntikeo N, Teh BT, Kukongviriyapan V. Haem oxygenase 1 expression is associated with prognosis in cholangiocarcinoma patients and with drug sensitivity in xenografted mice. Cell Prolif 2016;49:90-101. [PMID: 26726846 DOI: 10.1111/cpr.12228] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
179 Song W, Zhu ZG, Wu Q, Lv CG, Wang YG, Chen L, Miao DL. A nomogram to predict overall survival for biliary tract cancer. Cancer Manag Res 2018;10:1535-41. [PMID: 29942155 DOI: 10.2147/CMAR.S163291] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
180 Chamberlain CX, Faust E, Goldschmidt D, Webster N, Boscoe AN, Macaulay D, Peters ML. Burden of illness for patients with cholangiocarcinoma in the United States: a retrospective claims analysis. J Gastrointest Oncol 2021;12:658-68. [PMID: 34012657 DOI: 10.21037/jgo-20-544] [Reference Citation Analysis]
181 Mody K, Antwi SO, Hodge DO, Ailawadhi S, Roberts L, Bekaii-Saab T. A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin. J Gastrointest Oncol 2018;9:1063-73. [PMID: 30603125 DOI: 10.21037/jgo.2018.07.09] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
182 Huang XY, Zhang C, Cai JB, Shi GM, Ke AW, Dong ZR, Zhang PF, Fan J, Peng BG, Zhou J. Comprehensive multiple molecular profile of epithelial mesenchymal transition in intrahepatic cholangiocarcinoma patients. PLoS One. 2014;9:e96860. [PMID: 24816558 DOI: 10.1371/journal.pone.0096860] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
183 Pezzuto F, Izzo F, Buonaguro L, Annunziata C, Tatangelo F, Botti G, Buonaguro FM, Tornesello ML. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma. Oncotarget. 2016; Epub ahead of print. [PMID: 27276713 DOI: 10.18632/oncotarget.9801] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
184 Haga H, Yan I, Takahashi K, Wood J, Patel T. Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma. Gene Expr 2014;16:93-9. [PMID: 24801170 DOI: 10.3727/105221614X13919976902174] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
185 Ruzzenente A, Fassan M, Conci S, Simbolo M, Lawlor RT, Pedrazzani C, Capelli P, D’onofrio M, Iacono C, Scarpa A, Guglielmi A. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients. Ann Surg Oncol 2016;23:1699-707. [DOI: 10.1245/s10434-015-5046-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 7.2] [Reference Citation Analysis]
186 Li P, Zhang L, Yang M, Qi M, Jin X, Han B. Cul4B is a novel prognostic marker in cholangiocarcinoma. Oncol Lett 2017;14:1265-74. [PMID: 28808481 DOI: 10.3892/ol.2017.6297] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
187 Urbas R, Mayr C, Klieser E, Fuereder J, Bach D, Stättner S, Primavesi F, Jaeger T, Stanzer S, Ress AL, Löffelberger M, Wagner A, Berr F, Ritter M, Pichler M, Neureiter D, Kiesslich T. Relevance of MicroRNA200 Family and MicroRNA205 for Epithelial to Mesenchymal Transition and Clinical Outcome in Biliary Tract Cancer Patients. Int J Mol Sci 2016;17:E2053. [PMID: 27941621 DOI: 10.3390/ijms17122053] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
188 Dong M, Liu X, Evert K, Utpatel K, Peters M, Zhang S, Xu Z, Che L, Cigliano A, Ribback S, Dombrowski F, Cossu A, Gordan J, Calvisi DF, Evert M, Liu Y, Chen X. Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. Cell Death Dis 2018;9:31. [PMID: 29348467 DOI: 10.1038/s41419-017-0183-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
189 Resende V, Santos JP, Gomes RV, Vidigal PV, Pedrosa MS. Papillary neoplasias of the biliary tract. Rev Col Bras Cir 2014;41:445-50. [PMID: 25742412 DOI: 10.1590/0100-69912014006011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
190 Che L, Fan B, Pilo MG, Xu Z, Liu Y, Cigliano A, Cossu A, Palmieri G, Pascale RM, Porcu A, Vidili G, Serra M, Dombrowski F, Ribback S, Calvisi DF, Chen X. Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans. Oncogenesis 2016;5:e274. [PMID: 27918553 DOI: 10.1038/oncsis.2016.73] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
191 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
192 Nie J, Zhang J, Wang L, Lu L, Yuan Q, An F, Zhang S, Jiao Y. Adipocytes promote cholangiocarcinoma metastasis through fatty acid binding protein 4. J Exp Clin Cancer Res 2017;36:183. [PMID: 29237483 DOI: 10.1186/s13046-017-0641-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
193 强勇, 陈钟. EMT相关分子标志物在胆管癌侵袭转移中的研究进展. 世界华人消化杂志 2015; 23(25): 4051-4059 [DOI: 10.11569/wcjd.v23.i25.4051] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
194 Roeksomtawin S, Navasumrit P, Waraprasit S, Parnlob V, Sricharunrat T, Bhudhisawasdi V, Savaraj N, Ruchirawat M. Decreased argininosuccinate synthetase expression in Thai patients with cholangiocarcinoma and the effects of ADI-PEG20 treatment in CCA cell lines. Oncol Lett 2018;16:1529-38. [PMID: 30008833 DOI: 10.3892/ol.2018.8807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
195 Gradilone SA, Pisarello MJL, LaRusso NF. Primary Cilia in Tumor Biology: The Primary Cilium as a Therapeutic Target in Cholangiocarcinoma. Curr Drug Targets 2017;18:958-63. [PMID: 25706257 DOI: 10.2174/1389450116666150223162737] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
196 Klinhom-On N, Seubwai W, Sawanyawisuth K, Obchoei S, Mahalapbutr P, Wongkham S. FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase. Life Sci 2021;286:120072. [PMID: 34688691 DOI: 10.1016/j.lfs.2021.120072] [Reference Citation Analysis]
197 Kasuya G, Terashima K, Shibuya K, Toyama S, Ebner DK, Tsuji H, Okimoto T, Ohno T, Shioyama Y, Nakano T, Kamada T; Japan Carbon-Ion Radiation Oncology Study Group. Carbon-ion radiotherapy for cholangiocarcinoma: a multi-institutional study by and the Japan carbon-ion radiation oncology study group (J-CROS). Oncotarget 2019;10:4369-79. [PMID: 31320991 DOI: 10.18632/oncotarget.27028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
198 Baiocchi L, Sato K, Ekser B, Kennedy L, Francis H, Ceci L, Lenci I, Alvaro D, Franchitto A, Onori P, Gaudio E, Wu C, Chakraborty S, Glaser S, Alpini G. Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy. Expert Opin Investig Drugs 2021;30:365-75. [PMID: 33226854 DOI: 10.1080/13543784.2021.1854725] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
199 Waseem D, Tushar P. Intrahepatic, perihilar and distal cholangiocarcinoma: Management and outcomes. Ann Hepatol. 2017;16:133-139. [PMID: 28051802 DOI: 10.5604/16652681.1226927] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 8.8] [Reference Citation Analysis]
200 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
201 Won J, Ju JW, Kim SM, Shin Y, Chung S, Pak JH. Clonorchis sinensis infestation promotes three-dimensional aggregation and invasion of cholangiocarcinoma cells. PLoS One 2014;9:e110705. [PMID: 25340585 DOI: 10.1371/journal.pone.0110705] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
202 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
203 Du X, Zhang C, Yin C, Wang W, Yan X, Xie D, Zheng X, Zheng Q, Li M, Song Z. High BLM Expression Predicts Poor Clinical Outcome and Contributes to Malignant Progression in Human Cholangiocarcinoma. Front Oncol 2021;11:633899. [PMID: 33828983 DOI: 10.3389/fonc.2021.633899] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
204 Floreani A, Lisiero M, Baldovin T, Baldo V. Epidemiological aspects of biliary tree tumors in a region of northern Italy: emerging trends and sex-based differences. Eur J Gastroenterol Hepatol 2013;25:1347-51. [PMID: 24081106 DOI: 10.1097/MEG.0b013e3283636cfb] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
205 Mayr C, Wagner A, Loeffelberger M, Bruckner D, Jakab M, Berr F, Di Fazio P, Ocker M, Neureiter D, Pichler M. The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. Oncotarget. 2016;7:745-758. [PMID: 26623561 DOI: 10.18632/oncotarget.6378] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
206 Patel T. Extracellular vesicle noncoding RNA: new players in the diagnosis and pathogenesis of cholangiocarcinoma. Hepatology 2014;60:782-4. [PMID: 24753059 DOI: 10.1002/hep.27185] [Cited by in Crossref: 14] [Cited by in F6Publishing: 59] [Article Influence: 2.0] [Reference Citation Analysis]
207 Hongsrichan N, Rucksaken R, Chamgramol Y, Pinlaor P, Techasen A, Yongvanit P, Khuntikeo N, Pairojkul C, Pinlaor S. Annexin A1: A new immunohistological marker of cholangiocarcinoma. World J Gastroenterol 2013; 19(16): 2456-2465 [PMID: 23674846 DOI: 10.3748/wjg.v19.i16.2456] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
208 Boilève A, Hilmi M, Delaye M, Tijeras-Raballand A, Neuzillet C. Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice? Cancers (Basel) 2021;13:2708. [PMID: 34070929 DOI: 10.3390/cancers13112708] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
209 Wang Y, Ding M, Zhang Q, Wang J, Yang X, Zhou F, Li L, Yuan Z, Jin H, Qian Q. Activation or suppression of the immune response mediators in biliary tract cancer (BTC) patients: a systematic review and meta-analysis. J Cancer 2017;8:74-84. [PMID: 28123600 DOI: 10.7150/jca.16774] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
210 Kipp BR, Voss JS, Kerr SE, Barr Fritcher EG, Graham RP, Zhang L, Highsmith WE, Zhang J, Roberts LR, Gores GJ. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012;43:1552-1558. [PMID: 22503487 DOI: 10.1016/j.humpath.2011.12.007] [Cited by in Crossref: 137] [Cited by in F6Publishing: 140] [Article Influence: 15.2] [Reference Citation Analysis]
211 Zhu H, Han C, Lu D, Wu T. miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator. Am J Pathol. 2014;184:2828-2839. [PMID: 25239565 DOI: 10.1016/j.ajpath.2014.06.024] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 9.8] [Reference Citation Analysis]
212 Zhou L, Luo X. Platelet to lymphocyte ratio in biliary tract cancer: Review and meta-analysis. Clinica Chimica Acta 2017;474:102-7. [DOI: 10.1016/j.cca.2017.09.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
213 Lourdusamy V, Tharian B, Navaneethan U. Biomarkers in bile-complementing advanced endoscopic imaging in the diagnosis of indeterminate biliary strictures. World J Gastrointest Endosc 2015; 7(4): 308-317 [PMID: 25901209 DOI: 10.4253/wjge.v7.i4.308] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
214 Rodríguez de Lope C, Reig ME, Darnell A, Forner A. Approach of the patient with a liver mass. Frontline Gastroenterol 2012;3:252-62. [PMID: 28839677 DOI: 10.1136/flgastro-2012-100146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
215 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
216 Mody K, Starr J, Saul M, Poorman K, Weinberg BA, Salem ME, VanderWalde A, Shields AF. Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers. J Gastrointest Oncol 2019;10:1099-109. [PMID: 31949927 DOI: 10.21037/jgo.2019.08.08] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
217 Goeppert B, Frauenschuh L, Zucknick M, Roessler S, Mehrabi A, Hafezi M, Stenzinger A, Warth A, Pathil A, Renner M, Schirmacher P, Weichert W. Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer. Br J Cancer 2015;113:1343-9. [PMID: 26461054 DOI: 10.1038/bjc.2015.337] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.8] [Reference Citation Analysis]
218 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
219 Rana A, Hong JC. Orthotopic liver transplantation in combination with neoadjuvant therapy: a new paradigm in the treatment of unresectable intrahepatic cholangiocarcinoma. Current Opinion in Gastroenterology 2012;28:258-65. [DOI: 10.1097/mog.0b013e32835168db] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
220 Wang XP, Song J, Liu GT, Wang JJ, Guo HF. Upregulation of gastric adenocarcinoma predictive long intergenic non-coding RNA promotes progression and predicts poor prognosis in perihilar cholangiocarcinoma. Oncol Lett 2018;16:3964-72. [PMID: 30128015 DOI: 10.3892/ol.2018.9137] [Reference Citation Analysis]
221 Mayr C, Wagner A, Neureiter D, Pichler M, Jakab M, Illig R, Berr F, Kiesslich T. The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells. BMC Complement Altern Med 2015;15:194. [PMID: 26100134 DOI: 10.1186/s12906-015-0721-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
222 Di Tommaso L, Spadaccini M, Donadon M, Personeni N, Elamin A, Aghemo A, Lleo A. Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol 2019; 25(40): 6041-6052 [PMID: 31686761 DOI: 10.3748/wjg.v25.i40.6041] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
223 Zhang J, Han C, Wu T. MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin. Gastroenterology. 2012;143:246-56.e8. [PMID: 22484120 DOI: 10.1053/j.gastro.2012.03.045] [Cited by in Crossref: 117] [Cited by in F6Publishing: 121] [Article Influence: 13.0] [Reference Citation Analysis]
224 Sibulesky L, Nguyen J, Patel T. Preneoplastic conditions underlying bile duct cancer. Langenbecks Arch Surg 2012;397:861-7. [PMID: 22391777 DOI: 10.1007/s00423-012-0943-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
225 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
226 Lederer A, Herrmann P, Seehofer D, Dietel M, Pratschke J, Schlag P, Stein U. Metastasis-associated in colon cancer 1 is an independent prognostic biomarker for survival in Klatskin tumor patients. Hepatology. 2015;62:841-850. [PMID: 25953673 DOI: 10.1002/hep.27885] [Cited by in Crossref: 17] [Cited by in F6Publishing: 65] [Article Influence: 2.8] [Reference Citation Analysis]
227 Arnold A, Bahra M, Lenze D, Bradtmöller M, Guse K, Gehlhaar C, Bläker H, Heppner FL, Koch A. Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay. Experimental and Molecular Pathology 2015;99:344-53. [DOI: 10.1016/j.yexmp.2015.08.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
228 Zhi XS, Xiong J, Zi XY, Hu YP. The potential role of liver stem cells in initiation of primary liver cancer. Hepatol Int. 2016;10:893-901. [PMID: 27139191 DOI: 10.1007/s12072-016-9730-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
229 Salvador VB, Samrao P, Leytin A, Basith M. Atypical presentation of an advanced obstructive biliary cancer without jaundice. Am J Case Rep 2013;14:462-6. [PMID: 24223234 DOI: 10.12659/AJCR.889620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
230 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
231 Zheng S, Shen H, Jia Q, Jing C, Lin J, Zhang M, Zhang X, Zhang B, Liu Y. S100A6 promotes proliferation of intrahepatic cholangiocarcinoma cells via the activation of the p38/MAPK pathway. Future Oncology 2017;13:2053-63. [DOI: 10.2217/fon-2017-0199] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
232 Tal AO, Vermehren J, Friedrich-Rust M, Bojunga J, Sarrazin C, Zeuzem S, Trojan J, Albert JG. Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction. World J Gastrointest Endosc 2014; 6(1): 13-19 [PMID: 24527176 DOI: 10.4253/wjge.v6.i1.13] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 51] [Article Influence: 8.7] [Reference Citation Analysis]
233 Wang W, Tian SL, Jin D, Liu B, Wang W, Chang H, Chen C, Yu Z, Wang YZ, Li YL. The role of bile acid subtypes in the diagnosis of cholangiocarcinoma. Asia Pac J Clin Oncol 2021. [PMID: 34161672 DOI: 10.1111/ajco.13588] [Reference Citation Analysis]
234 Xiao M, Gao Y, Wang Y. Helicobacter species infection may be associated with cholangiocarcinoma: a meta-analysis. Int J Clin Pract 2014;68:262-70. [DOI: 10.1111/ijcp.12264] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
235 Simbolo M, Fassan M, Ruzzenente A, Mafficini A, Wood LD, Corbo V, Melisi D, Malleo G, Vicentini C, Malpeli G, Antonello D, Sperandio N, Capelli P, Tomezzoli A, Iacono C, Lawlor RT, Bassi C, Hruban RH, Guglielmi A, Tortora G, de Braud F, Scarpa A. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget 2014;5:2839-52. [PMID: 24867389 DOI: 10.18632/oncotarget.1943] [Cited by in Crossref: 101] [Cited by in F6Publishing: 153] [Article Influence: 16.8] [Reference Citation Analysis]
236 Zhuang L, Yan X, Meng Z. Second primary malignancy in patients with cholangiocarcinoma: a population-based study. Cancer Manag Res 2019;11:1969-83. [PMID: 30881122 DOI: 10.2147/CMAR.S187614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
237 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
238 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
239 Gu Y, Zhu Z, Pei H, Xu D, Jiang Y, Zhang L, Xiao L. Long non-coding RNA NNT-AS1 promotes cholangiocarcinoma cells proliferation and epithelial-to-mesenchymal transition through down-regulating miR-203. Aging (Albany NY) 2020;12:2333-46. [PMID: 32019904 DOI: 10.18632/aging.102747] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
240 Saranaruk P, Kariya R, Sittithumcharee G, Boueroy P, Boonmars T, Sawanyawisuth K, Wongkham C, Wongkham S, Okada S, Vaeteewoottacharn K. Chromomycin A3 suppresses cholangiocarcinoma growth by induction of S phase cell cycle arrest and suppression of Sp1‑related anti‑apoptotic proteins. Int J Mol Med 2020;45:1005-16. [PMID: 32124934 DOI: 10.3892/ijmm.2020.4482] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
241 Lorenzo N, Sabina DM, Guido C, Ilaria Grazia Z, Samira S, Valeria A, Daniele C, Diletta O, Antonella G, Marco M, Daniela B, Valerio P, Andrea O, Agostino Maria R, Fabio M, Maria Consiglia B, Jessica F, Sara M, Gian Luca G, Pierluigi Benedetti P, Paquale Bartomeo B, Felice G, Vincenzo C, Pietro I, Giuseppina C, Eugenio G, Domenico A. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma. Hepatology 2021;73:144-59. [PMID: 32978808 DOI: 10.1002/hep.31571] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
242 Branchi V, Schaefer P, Semaan A, Kania A, Lingohr P, Kalff JC, Schäfer N, Kristiansen G, Dietrich D, Matthaei H. Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract. Clin Epigenetics 2016;8:133. [PMID: 27999621 DOI: 10.1186/s13148-016-0299-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
243 Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-80. [DOI: 10.1038/nrgastro.2016.51] [Reference Citation Analysis]
244 Moriconi F, Ramadori P, Schultze FC, Blaschke M, Amanzada A, Khan S, Ramadori G. Characterization of the erythropoietin/erythropoietin receptor axis in a rat model of liver damage and cholangiocarcinoma development. Histochem Cell Biol 2013;139:473-85. [PMID: 23052842 DOI: 10.1007/s00418-012-1037-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
245 Okabe H, Chikamoto A, Maruno M, Hashimoto D, Imai K, Taki K, Arima K, Ishiko T, Uchiyama H, Ikegami T, Harimoto N, Itoh S, Yoshizumi T, Beppu T, Baba H, Maehara Y. A long survivor with local relapse of hilar cholangiocarcinoma after R1 surgery treated with chemoradiotherapy: a case report and literature review. Surg Case Rep 2016;2:69. [PMID: 27376654 DOI: 10.1186/s40792-016-0195-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
246 Roest HP, Verhoeven CJ, van der Laan LJ. MicroRNAs in bile vesicles: Finding a trade‐off for biomarker discovery. Hepatology 2015;61:1094-5. [DOI: 10.1002/hep.27325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]